Auriga Reiterates a 'Buy' on Jazz Pharmaceuticals (JAZZ); Lifting Numbers on 'Beat & Raise'
Tweet Send to a FriendGet Alerts JAZZ Hot Sheet
Price: $58.36 +0.07%
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade JAZZ Now!
Auriga reiterates a 'Buy' on Jazz Pharmaceuticals (NASDAQ: JAZZ) price target raised from $57 to $64.
Auriga analyst, Difei Yang, said, "2012 started off as a good year for JAZZ. During Q1, the company closed the Azur Pharma acquisition ahead of schedule, and delivered a great quarter with better than expected financial performance due primarily to strong demand of Xyrem. Most recently, the company announced the plan to acquire EUSA for $650 million which translates to less than 3x 2013 sales. The deal is expected to be immediately accretive and adds about $0.80 to adjusted EPS in 2013....Strong Xyrem volume growth at over 10% y/y rate, coupled with the anticipated 19% price increase in January as well as a shipment of $4.6 million Prialt to Eisai for sale in Europe are largely accountable for the better than expected revenue growth."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $50.37 yesterday, with a 52 week range of $26.17-$54.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Auriga analyst, Difei Yang, said, "2012 started off as a good year for JAZZ. During Q1, the company closed the Azur Pharma acquisition ahead of schedule, and delivered a great quarter with better than expected financial performance due primarily to strong demand of Xyrem. Most recently, the company announced the plan to acquire EUSA for $650 million which translates to less than 3x 2013 sales. The deal is expected to be immediately accretive and adds about $0.80 to adjusted EPS in 2013....Strong Xyrem volume growth at over 10% y/y rate, coupled with the anticipated 19% price increase in January as well as a shipment of $4.6 million Prialt to Eisai for sale in Europe are largely accountable for the better than expected revenue growth."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $50.37 yesterday, with a 52 week range of $26.17-$54.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Macquarie Downgrades Barrick Gold (ABX) to Underperform
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Auriga
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
